

28 February 2025

Physiomics plc
("Physiomics" or "the Company")

Notice of Results and Investor Presentation

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce that it will be posting interim results on Thursday 6 March 2025.

The Company will provide a live presentation in-line with these results via Investor Meet Company on 10 March 2025 at 12:00 pm GMT. During this presentation, Peter Sargent (CEO) and Jim Millen (Chairman) would be happy to take questions relating to our interim results and more broadly about the business.

The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9 March 2025, 09:00 am GMT, or at any time during the live presentation.

Investors can sign up to Investor Meet Company for free and add to meet PHYSIOMICS PLC via:

<https://www.investormeetcompany.com/physiomics-plc/register-investor>

Investors who already follow PHYSIOMICS PLC on the Investor Meet Company platform will automatically be invited.

Enquiries:

Physiomics plc

Dr Peter Sargent, Chief Executive Officer, +44 (0)1865 784 980

Hybridan LLP (Broker)

Claire Louise Noyce
+44 (0) 203 764 2341

Strand Hanson Ltd (NOMAD)

James Dance & James Bellman
+44 (0)20 7409 3494

Notes to Editor

About Physiomics

Physiomics plc combines expertise across Modelling & Simulation, Biostatistics, Data Science and Bioinformatics, together with deep biology expertise, to help biotech and pharma companies streamline their drug development journeys. Our approach is to help derive insight from all relevant and often disparate data in order to de-risk

decision making and optimise research design across discovery, pre-clinical and clinical studies. Through use of cutting-edge computational tools, bespoke models and our proprietary Virtual Tumour technology, the Physiomics team has informed the development of over 100 commercial projects, with over 125 targets and drugs modelled. Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics & CRUK.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NORPPUMCPUPAGRM